Clinical dossier

Tirzepatide Evidence Profile

Last Updated: May 2026

An interactive research-focused summary of tirzepatide, a dual GIP and GLP-1 receptor agonist, with visualized outcomes across weight management, glycemic control, sleep apnea, liver disease, and cardiometabolic endpoints.

Dual GIP + GLP-1 agonist
20.9% mean weight reduction in SURMOUNT-1
SURMOUNT + SURPASS evidence base

Efficacy snapshot

A dual-incretin platform with broad clinical signals

Tirzepatide has been evaluated across large Phase 3 programs in obesity and type 2 diabetes, with additional research in obstructive sleep apnea, MASH, and heart failure with preserved ejection fraction in adults with obesity.

Designed around complementary incretin biology.

The molecule combines GLP-1 receptor activity, associated with satiety and glucose-dependent insulin secretion, with GIP receptor activity, which is studied for effects on insulin sensitivity, metabolic regulation, and adipose-tissue biology.

20.9% Mean body-weight reduction reported at 72 weeks in SURMOUNT-1 at 15 mg.
2.30% Mean HbA1c reduction reported in SURPASS-2 at 15 mg.
74% MASH resolution without worsening fibrosis reported in the high-dose SYNERGY-NASH group.

Weight-management durability

SURMOUNT-4 illustrates the chronic-care nature of obesity management: continued treatment maintained and extended weight reduction, while withdrawal was associated with regain.

Head-to-head evidence

SURMOUNT-5 compared tirzepatide with semaglutide in adults with obesity or overweight without diabetes, adding direct comparative context to the evidence base.

Beyond body weight

Evidence now includes clinically relevant endpoints in sleep apnea, liver disease, and obesity-related HFpEF, making tirzepatide one of the most extensively studied incretin therapies.

Pharmacology

Mechanism of action

Tirzepatide is an imbalanced dual agonist, engineered to favor GIP receptor binding over GLP-1 receptor binding, mimicking the natural metabolic synergy of endogenous incretin hormones.

GLP-1 Receptor Activity

Glucagon-like peptide-1 (GLP-1) agonism predominantly regulates glucose metabolism by enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion. It slows gastric emptying and operates centrally in the brain to signal satiety and reduce caloric intake.

GIP Receptor Activity

Glucose-dependent insulinotropic polypeptide (GIP) agonism acts synergistically with GLP-1. Modulating the GIP receptor has been shown in pre-clinical and clinical models to enhance insulin sensitivity, improve lipid metabolism, and regulate white adipose tissue function, limiting ectopic fat deposition.

Interactive infographics

Clinical data dashboard

Hover over the charts to review primary efficacy endpoints drawn from the SURMOUNT and SURPASS clinical programs. Charts will animate as you scroll them into view.

Weight Trajectory Over 72 Weeks
SURMOUNT-1: percentage change in body weight
Maintenance vs. Withdrawal
SURMOUNT-4: impact of stopping therapy after lead-in
Glycemic Control Endpoint
SURPASS-2: HbA1c reduction vs semaglutide 1 mg
Body Composition Quality
MRI subpopulation: fat mass vs lean mass loss ratio

Endpoint summary

Research landscape

A concise overview of the main clinical themes represented in tirzepatide's published and regulatory evidence base.

Research area Study / setting Reported signal Why it matters
Chronic weight management SURMOUNT-1; 72 weeks Up to 20.9% mean body-weight reduction at 15 mg Established dual-incretin therapy as a major pharmacologic approach for obesity research.
Obesity with Type 2 Diabetes SURMOUNT-2; 72 weeks Up to 15.7% mean body-weight reduction at 15 mg Demonstrated significant weight reduction in a clinical population typically resistant to weight loss.
Active comparator obesity SURMOUNT-5; 72 weeks 20.2% mean reduction with tirzepatide vs 13.7% with semaglutide Provides direct head-to-head context against a single GLP-1 receptor agonist.
Type 2 diabetes SURPASS-2; 40 weeks Up to 2.30% mean HbA1c reduction at 15 mg Demonstrated strong glycemic control against semaglutide 1 mg.
Obstructive sleep apnea SURMOUNT-OSA; 52 weeks Clinically meaningful reductions in apnea-hypopnea events Supported the first FDA approval of a medication for moderate-to-severe OSA in adults with obesity.
MASH / liver fibrosis SYNERGY-NASH; 52 weeks High-dose group reported 74% MASH resolution without worsening fibrosis Positions liver disease as a key cardiometabolic research extension.
HFpEF with obesity SUMMIT; median follow-up about two years Lower composite risk of cardiovascular death or worsening heart-failure event vs placebo Highlights the potential importance of incretin therapy in obesity-related heart failure research.

Additional resources

Recent evidence additions

Selected newer resources expand the page beyond the original obesity and diabetes dashboard.

SURMOUNT-5

Head-to-head comparison of tirzepatide versus semaglutide for obesity treatment without diabetes.

Review summary ↗

SUMMIT HFpEF

Obesity-related heart failure with preserved ejection fraction trial evaluating clinical outcomes and health status.

Review summary ↗

FDA OSA approval

Regulatory milestone for moderate-to-severe obstructive sleep apnea in adults with obesity.

FDA release ↗

Dossier tracks

Explore the research narrative

Select a clinical track below to review study architecture, published endpoints, and mechanistic context.

SURMOUNT-1: foundational obesity trial

Design: 72-week trial evaluating 2,539 adults with BMI ≥30, or ≥27 with comorbidities, without diabetes.

Outcomes: The 15 mg dose achieved a 20.9% mean body-weight reduction. A large majority of participants achieved at least 5% weight reduction, establishing a high benchmark for pharmacologic obesity treatment.

20.9% weight reduction n=2,539 72 weeks

SURMOUNT-3: lifestyle intervention lead-in

Design: Tirzepatide was evaluated after a 12-week intensive lifestyle intervention, where participants had already lost weight through diet and activity changes.

Outcomes: Adding tirzepatide was associated with an additional 21.1% weight reduction, with total mean reduction from study entry reported at 26.6%.

Lifestyle lead-in 26.6% total reduction

SURMOUNT-4: maintenance and withdrawal

Design: Participants completed a 36-week open-label lead-in, followed by randomized continuation of tirzepatide or switch to placebo.

Outcomes: Continued tirzepatide maintained and extended weight reduction, while withdrawal was associated with substantial weight regain.

Maintenance study Chronic-care signal

SURPASS-2: superiority over semaglutide

Design: 40-week direct comparison of tirzepatide 5, 10, and 15 mg against semaglutide 1 mg in type 2 diabetes.

Outcomes: Tirzepatide 15 mg reduced HbA1c by 2.30% compared with 1.86% for semaglutide and produced greater mean body-weight reduction.

-2.30% HbA1c Active comparator

SURMOUNT-2: obesity with type 2 diabetes

Design: 72-week trial in 938 adults with obesity or overweight and type 2 diabetes.

Outcomes: The 15 mg dose achieved a 15.7% mean body-weight reduction alongside significant improvements in glycemic control, notable for a population historically resistant to pharmacologic weight loss.

15.7% weight reduction n=938

SURPASS-4: cardiovascular risk cohort

Design: Study in participants with type 2 diabetes and increased cardiovascular risk, comparing tirzepatide against titrated insulin glargine.

Outcomes: Tirzepatide produced stronger glycemic control and weight reduction compared with insulin glargine, with cardiovascular safety evaluated in a higher-risk population.

SURMOUNT-OSA: obstructive sleep apnea

Outcomes: Tirzepatide reduced apnea-hypopnea burden in adults with obesity and moderate-to-severe obstructive sleep apnea, supporting a major new treatment pathway in this population.

OSA endpoint FDA approval support

SYNERGY-NASH: MASH and fibrosis

Outcomes: The high-dose group reported 74% MASH resolution without worsening fibrosis, with a meaningful proportion also showing fibrosis-stage improvement.

74% MASH resolution Fibrosis endpoint

SUMMIT: HFpEF with obesity

Outcomes: In adults with obesity and heart failure with preserved ejection fraction, tirzepatide lowered the composite risk of cardiovascular death or worsening heart-failure events compared with placebo and improved health-status measures.

HFpEF Clinical outcomes

Protocol overview

Step-up titration schedule

A five-step overview of the dose-escalation structure used to support tolerability in clinical protocols.

Month 1
2.5 mg
Initiation dose. Not intended as a maintenance dose.
Month 2
5.0 mg
First maintenance dose option.
Month 3
7.5 mg
Escalation step for continued response.
Month 4
10.0 mg
Secondary maintenance dose option.

Terminology

Glossary of terms

Incretin Hormones


Metabolic hormones (like GLP-1 and GIP) that are released from the gut into the bloodstream in response to food ingestion, helping to lower blood glucose levels by stimulating insulin release and reducing appetite.

GIP vs. GLP-1


GLP-1 (Glucagon-like peptide-1) primarily regulates appetite and glucose-dependent insulin secretion. GIP (Glucose-dependent insulinotropic polypeptide) acts synergistically to improve insulin sensitivity, regulate lipid metabolism, and may mitigate some GLP-1 related tolerability issues.

HFpEF


Heart Failure with Preserved Ejection Fraction. A condition where the heart pumps normally but is too stiff to fill properly. Incretin therapies are actively being researched for cardiovascular outcome improvements in HFpEF patients with obesity.

OSA


Obstructive Sleep Apnea. A sleep-related breathing disorder characterized by repeated episodes of complete or partial airway obstruction.

Researcher FAQ

Frequently asked questions

Why is dual agonism clinically important?


Dual agonism combines GLP-1 receptor activity with GIP receptor activity, creating a differentiated incretin profile that has been associated with strong body-weight and glycemic outcomes in clinical research. GIP synergy is hypothesized to mitigate some GLP-1 related nausea while promoting improved lipid metabolism and insulin sensitivity.

What is the most common safety-profile concern?


The most frequent adverse events are gastrointestinal, including nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal discomfort. These events are typically most prominent during dose escalation and are generally mild to moderate in severity. A step-up titration schedule is utilized to mitigate these effects.

Are there major contraindications to be aware of?


Yes. Tirzepatide, like other incretin-based therapies, carries warnings regarding a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients with a history of severe gastrointestinal disease (e.g., severe gastroparesis) or a history of pancreatitis are typically excluded from trials and advised caution or alternative therapies.

Does tirzepatide cause lean-mass loss?


During substantial weight reduction, some lean-mass reduction is expected. Body-composition analyses suggest that most lost mass is fat mass (roughly 75%), with meaningful improvement in overall body composition and cardiometabolic health parameters.

Why does withdrawal matter in SURMOUNT-4?


The withdrawal design helps show whether weight reduction is sustained after treatment stops. In SURMOUNT-4, continued treatment maintained and extended weight reduction, while switching to placebo was associated with significant weight regain, demonstrating that obesity generally requires chronic management.

Why include OSA, MASH, and HFpEF resources?


These areas show how tirzepatide research has moved beyond weight and glucose endpoints into obesity-related comorbidities, including sleep-disordered breathing, liver disease, and heart-failure outcomes. This underscores a systemic metabolic improvement rather than just isolated weight loss.

References & source data

  • SURMOUNT-1: Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
  • SURMOUNT-2: Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. The Lancet. https://doi.org/10.1016/S0140-6736(23)01200-X
  • SURMOUNT-3: Wadden, T. A., et al. (2023). Tirzepatide after intensive lifestyle intervention for adults with overweight or obesity. Nature Medicine. https://doi.org/10.1038/s41591-023-02597-w
  • SURMOUNT-4: Aronne, L. J., et al. (2023). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. https://doi.org/10.1001/jama.2023.24945
  • SURMOUNT-5: Aronne, L. J., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. The New England Journal of Medicine. ACC study summary
  • SURPASS-2: Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2107519
  • SURPASS-4: Del Prato, S., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk. The Lancet. https://doi.org/10.1016/S0140-6736(21)02188-7
  • SURMOUNT-OSA: Malhotra, A., et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2404881
  • SYNERGY-NASH: Loomba, R., et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2401943
  • SUMMIT HFpEF: Tirzepatide for heart failure with preserved ejection fraction and obesity. ACC trial summary
  • Regulatory milestone: FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. FDA press announcement
Research view